Dragon's blood
"Dragon's Blood"(DB) has become increasingly popular in Europe and the USA this year. Marketed as an anti-ageing compound within cosmetics, DB is a deep red resin secreted from the fruit of the dragon tree species, Daemonorops draco. Scientists in China 2 believe they have identified two novel biomarkers that could be used in the QC of DB.
‘Dragon’s Blood’ (DB) has become increasingly popular in Europe and the USA this year. Marketed as an anti‑ageing compound within cosmetics, DB is a deep red resin secreted from the fruit of the dragon tree species, Daemonorops draco. Historically used in Chinese medicine to improve blood circulation for the treatment of traumatic injuries, it also has reported antimicrobial, antiviral, antitumor and cytotoxic activity.1 However, as with the claims of many other cosmetics and herbal preparations, the actual concentrations of active ingredients are often below the effective level for action.
At the present time, there is only one biomarker that is quantified for quality control (QC) purposes within Dragon’s Blood, dracorhodin, and as there is an inherent variability in biomarker concentration this is an unreliable quality control method. Scientists in China 2 believe they have identified two novel biomarkers that could be used in the QC of DB. Using ultra-high performance liquid chromatography (UHPLC) coupled with a photodiode array (PAD) and electron ionization mass spectrometry (ESI‑MS), the scientists characterized six flavenoids known to be contained in the DB resin. The scientists identified two novel potential biomarkers, (2S)-5-methoxyflavan-7-ol and (2S)‑5‑methoxy-6-methylfavan-7-ol. It is hoped that with further investigation, the QC analysis method used will improve the quality of DB products.
1. J. Shi et al, J Sep Sci. 32(23–24), 4040–7 (2009).
2. T. Yi et al, Chemistry Central Journal, 6(116)(2012).
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
